Dr. Reddy’s Laboratories Ltd ADR annual ebitda for fiscal 2026 was ₹83.3 billion, a decrease of 13.8% from ₹96.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-09-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | ₹83.3B | ₹96.7B | ₹88.4B | ₹74.4B | ₹45.1B | ₹535M | ₹41.8B | ₹35.5B | ₹23.6B | ₹24.8B | ₹39.9B | ₹34.4B | ₹33.1B | ₹22.5B | ₹20.3B | ₹16.8B | ₹6.6B | ₹1.5B | ₹7.3B | ₹14.3B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | ₹3.0B | ₹8.8B | ₹19.6B | ₹24.3B | ₹24.6B | ₹25.3B | ₹24.3B | ₹23.9B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More RDY metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All RDY financial statements → Interactive RDY charts →
About TickerBase · Data methodology & sources · Privacy · Terms